EGFR dysregulation is likely associated with non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, and pancreatic cancer [83,86]; thus, it is a potential target for cancer therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.